Literature DB >> 31234672

Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain.

Pamela Vo1, Wei Gao2, Miriam L Zichlin2, Eleanore Fuqua2, Ela Fadli2, Marta Aguirre Vazquez3, Thaïs Tarancón3, Nicolas Mahieu4, Monika Maier-Peuschel5, Silvia Rossi6, Mariantonietta Naclerio6, Daniela Ritrovato6, Elyse Swallow2.   

Abstract

Aims: This retrospective chart review examined the six-month migraine-related healthcare resource use (HRU) among European patients who had ≥4 migraine days per month and previously failed at least two prophylactic migraine treatments.
Methods: Neurologists, headache specialists, and pain specialists in France, Germany, Italy, and Spain who treated ≥10 patients with migraine in 2017 were recruited (April-June 2018) to extract anonymized patient-level data. Eligible physicians randomly selected charts of up to five adult patients with clinically-confirmed migraine, ≥4 migraine days in the month prior to the index date, and had previously failed at least two prophylactic migraine treatments. Treatment failure was defined as discontinuation due to lack of efficacy and/or tolerability. Demographic and disease characteristics as of the index date, and migraine-related HRU incurred during the 6-month study period, were recorded.
Results: A total of 104 physicians contributed 168 charts for patients (63% female). On average, patients were 38 years old and failed 2.3 prophylactic treatments as of the index date. During the study period, 83% of patients had ≥1 outpatient visit for migraine in the physician's office, and 27% went to the ER/A&E. Approximately 5% of patients were hospitalized for migraine, with an average of one hospitalization and an average length of stay of 3 days. Approximately 39% of patients had ≥1 blood test, 22% had ≥1 magnetic resonance imaging, 17% had ≥1 electroencephalogram, and 13% had ≥1 computerized tomography scan. Visits to other healthcare providers were common. Limitations: This study is subject to the limitations of chart review studies, such as errors in data entry. Conclusions: Across four European countries, the HRU burden of migraine among patients who previously failed at least two prophylactic treatments was high, indicating a need for more effective prophylactic treatments to appropriately manage migraine and reduce the HRU burden attributable to this common disorder.

Entities:  

Keywords:  Europe; H51; I11; Migraine; disease burden; real-world; treatment failure

Mesh:

Year:  2019        PMID: 31234672     DOI: 10.1080/13696998.2019.1636051

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  2 in total

1.  Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study.

Authors:  Pablo Irimia; David García-Azorín; Mercedes Núñez; Sílvia Díaz-Cerezo; Pepa García de Polavieja; Tommaso Panni; Aram Sicras-Navarro; Antoni Sicras-Mainar; Antonio Ciudad
Journal:  J Headache Pain       Date:  2022-07-07       Impact factor: 8.588

2.  Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.

Authors:  Ariane K Kawata; Neel Shah; Jiat-Ling Poon; Shannon Shaffer; Sandhya Sapra; Teresa K Wilcox; Shweta Shah; Stewart J Tepper; David W Dodick; Richard B Lipton
Journal:  Headache       Date:  2021-02-16       Impact factor: 5.887

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.